Immunocore (NASDAQ:IMCR) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Immunocore (NASDAQ:IMCR) from a hold rating to a buy rating in a research note released on Monday morning.

A number of other equities analysts have also recently weighed in on IMCR. HC Wainwright reissued a “buy” rating and issued a $100.00 price target on shares of Immunocore in a report on Monday, April 20th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Immunocore in a research note on Tuesday, April 21st. Zacks Research cut Immunocore from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 7th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Immunocore in a research note on Monday, July 13th. Five research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Immunocore currently has an average rating of “Hold” and a consensus target price of $56.71.

Immunocore Trading Up 3.1%

Shares of Immunocore stock opened at $35.54 on Monday. The company has a debt-to-equity ratio of 1.00, a current ratio of 4.18 and a quick ratio of 4.15. Immunocore has a 1 year low of $27.56 and a 1 year high of $40.71. The company has a market capitalization of $1.81 billion, a P/E ratio of -64.62 and a beta of 0.73. The business has a 50 day moving average price of $30.46 and a 200 day moving average price of $31.27.

Immunocore (NASDAQ:IMCR) last announced its earnings results on Wednesday, May 6th. The company reported $0.25 EPS for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.51. The firm had revenue of $106.68 million for the quarter, compared to analysts’ expectations of $145.20 million. Immunocore had a negative return on equity of 7.07% and a negative net margin of 6.68%.Immunocore’s quarterly revenue was up 13.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.10 EPS. Sell-side analysts anticipate that Immunocore will post 0.06 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Leonteq Securities AG acquired a new stake in shares of Immunocore during the fourth quarter worth $30,000. Harbour Investments Inc. grew its position in shares of Immunocore by 60.2% in the fourth quarter. Harbour Investments Inc. now owns 1,033 shares of the company’s stock valued at $36,000 after purchasing an additional 388 shares during the period. Rockefeller Capital Management L.P. acquired a new position in Immunocore in the fourth quarter valued at $47,000. Arax Advisory Partners increased its stake in Immunocore by 302.9% in the fourth quarter. Arax Advisory Partners now owns 1,386 shares of the company’s stock valued at $48,000 after purchasing an additional 1,042 shares during the last quarter. Finally, GAMMA Investing LLC lifted its position in Immunocore by 202.8% during the second quarter. GAMMA Investing LLC now owns 1,920 shares of the company’s stock worth $61,000 after buying an additional 1,286 shares during the period. Hedge funds and other institutional investors own 84.50% of the company’s stock.

Immunocore Company Profile

Immunocore plc is a clinical‐stage biotechnology company focused on the development of novel immunotherapies that harness the body’s own T‐cell response to treat cancer and infectious diseases. The company’s proprietary ImmTAC (immune mobilising monoclonal T‐cell receptors against cancer) platform utilizes engineered, soluble T‐cell receptor (TCR) molecules designed to recognise intracellular peptide–HLA complexes. By redirecting and activating T cells against disease‐associated targets, Immunocore aims to address malignancies and persistent viral infections with high unmet medical need.

The company’s most advanced candidate, tebentafusp, is a bispecific ImmTAC molecule that targets gp100, a melanoma‐associated antigen, and has received regulatory approval for the treatment of metastatic uveal melanoma.